Drug Search Results
More Filters [+]

Farglitazar

Alternative Names: farglitazar, gi-262570, gi262570, gi 262570
Latest Update: 2017-12-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Farglitazar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis C, Chronic|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FBX104114

P2

Completed

Hepatitis C, Chronic|Liver Cirrhosis

2008-03-13

2005-000995-41

P2

Completed

Hepatitis C, Chronic

2008-02-29

Recent News Events

Date

Type

Title